Literature DB >> 19688296

Pharmacokinetic analysis of etoposide distribution after administration directly into the fourth ventricle in a piglet model.

David I Sandberg1, Kenneth M Crandall, Tulay Koru-Sengul, Kyle R Padgett, John Landrum, Darwin Babino, Carol K Petito, Juan Solano, Manuel Gonzalez-Brito, John W Kuluz.   

Abstract

We hypothesize that infusion of chemotherapeutic agents directly into the fourth ventricle potentially may play a role in treating malignant posterior fossa brain tumors. Accordingly, we used a piglet model developed in our laboratory to test the safety of etoposide infusions into the fourth ventricle and to study the pharmacokinetics associated with these infusions. In 5 piglets, closed-tip silicone catheters were inserted into the fourth ventricle and lumbar cistern. Five consecutive daily infusions of etoposide (0.5 mg) were administered via the fourth ventricle catheter. Serum and CSF from both catheters were sampled for measurement of etoposide level by reversed-phase high performance liquid chromatography (HPLC). For CSF samples, area under the concentration-time curve (AUC) was calculated. Piglets underwent daily neurological examinations, a 4.7 Tesla MRI scan, and then were sacrificed for post-mortem brain examination. No neurological deficits or signs of meningitis were caused by intraventricular chemotherapy infusions. MRI scans showed catheter placement within the fourth ventricle but no signal changes in the brain stem or cerebellum. In all piglets, the mean fourth ventricular CSF peak etoposide level exceeded the mean peak lumbar etoposide levels by greater than 10-fold. Statistically significant differences between fourth ventricle and lumbar AUC were noted at peaks (DeltaAUC = 3384196 ng h/ml with 95%CI: 1758625, 5009767, P = 0.0044) and at all collection time points (DeltaAUC = 1422977 ng h/ml with 95%CI: 732188, 2113766, P = 0.0046) but not at troughs (DeltaAUC = -29546 ng h/ml (95%CI: -147526, 88434.2, P = 0.5251). Serum etoposide was absent at two and four hours after intraventricular infusions in all animals. Pathological analysis demonstrated meningitis, choroid plexitis, and ependymitis in the fourth and occasionally lateral ventricles. Etoposide can be infused directly into the fourth ventricle without clinical or radiographic evidence of damage. Autopsy examination revealed ventriculitis and meningitis which did not have a clinical correlate. Etoposide does not distribute evenly throughout CSF spaces after administration into the fourth ventricle, and higher peak CSF levels are observed in the fourth ventricle than in the lumbar cistern.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19688296     DOI: 10.1007/s11060-009-9998-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  22 in total

Review 1.  Medulloblastoma.

Authors:  J T Rutka
Journal:  Clin Neurosurg       Date:  1997

2.  Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients.

Authors:  S Reif; D Kingreen; C Kloft; J Grimm; W Siegert; W Schunack; U Jaehde
Journal:  Cancer Chemother Pharmacol       Date:  2001-08       Impact factor: 3.333

3.  Cerebrospinal fluid pharmacokinetics after different dosage regimens of intraventricular etoposide.

Authors:  C Sirisangtragul; G Henke; G Fleischhack; S Reif; C Kloft; U Bode; U Jaehde
Journal:  Int J Clin Pharmacol Ther       Date:  2003-12       Impact factor: 1.366

Review 4.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

5.  The Ommaya reservoir in chemotherapy for malignant disease in the CNS.

Authors:  A Jacobs; P Clifford; H E Kay
Journal:  Clin Oncol       Date:  1981-06

Review 6.  Neurologic complications of chemotherapy.

Authors:  D R Macdonald
Journal:  Neurol Clin       Date:  1991-11       Impact factor: 3.806

7.  Chemotherapy administration directly into the fourth ventricle in a new piglet model. Laboratory Investigation.

Authors:  David I Sandberg; Kenneth M Crandall; Carol K Petito; Kyle R Padgett; John Landrum; Darwin Babino; Danshe He; Juan Solano; Manuel Gonzalez-Brito; John W Kuluz
Journal:  J Neurosurg Pediatr       Date:  2008-05       Impact factor: 2.375

8.  Cerebellar medulloblastoma: the importance of posterior fossa dose to survival and patterns of failure.

Authors:  C L Silverman; J R Simpson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982-11       Impact factor: 7.038

9.  The Ommaya reservoir: newly recognized complications and recommendations for insertion and use.

Authors:  W A Bleyer; P A Pizzo; A M Spence; W D Platt; D R Benjamin; C J Kolins; D G Poplack
Journal:  Cancer       Date:  1978-06       Impact factor: 6.860

10.  Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours.

Authors:  G Fleischhack; S Reif; C Hasan; U Jaehde; S Hettmer; U Bode
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640

View more
  6 in total

1.  Safety and pharmacokinetic analysis of methotrexate administered directly into the fourth ventricle in a piglet model.

Authors:  David I Sandberg; Juan Solano; Carol K Petito; Abdul Mian; Caihong Mou; Tulay Koru-Sengul; Manuel Gonzalez-Brito; Kyle R Padgett; Ali Luqman; Juan Carlos Buitrago; Farid Alam; Jerome R Wilkerson; Kenneth M Crandall; John W Kuluz
Journal:  J Neurooncol       Date:  2010-05-04       Impact factor: 4.130

2.  Fate of nanoparticles in the central nervous system after intrathecal injection in healthy mice.

Authors:  K T Householder; S Dharmaraj; D I Sandberg; R J Wechsler-Reya; R W Sirianni
Journal:  Sci Rep       Date:  2019-08-29       Impact factor: 4.379

3.  High-dose MTX110 (soluble panobinostat) safely administered into the fourth ventricle in a nonhuman primate model.

Authors:  David I Sandberg; Natasha Kharas; Bangning Yu; Christopher F Janssen; Amanda Trimble; Leomar Y Ballester; Rajan Patel; Afroz S Mohammad; William F Elmquist; Rachael W Sirianni
Journal:  J Neurosurg Pediatr       Date:  2020-05-01       Impact factor: 2.375

Review 4.  Utility of CSF in translational neuroscience.

Authors:  Elizabeth C M de Lange
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-02-12       Impact factor: 2.745

5.  Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trial.

Authors:  David I Sandberg; Michael Rytting; Wafik Zaky; Marcia Kerr; Leena Ketonen; Uma Kundu; Bartlett D Moore; Grace Yang; Ping Hou; Clark Sitton; Laurence J Cooper; Vidya Gopalakrishnan; Dean A Lee; Peter F Thall; Soumen Khatua
Journal:  J Neurooncol       Date:  2015-08-09       Impact factor: 4.130

6.  Ventricular access device placement in the fourth ventricle to treat malignant fourth ventricle brain tumors: technical note.

Authors:  David I Sandberg; Marcia L Kerr
Journal:  Childs Nerv Syst       Date:  2015-11-23       Impact factor: 1.475

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.